Given the potential of multitarget strategies in overcoming resistance, ongoing trials are investigating the combination of nivolumab, decitabine, and venetoclax in treatment‐naïve TP53‐mutated AML (NCT04277442). The gene discussed is TP53; the disease is acute myeloid leukemia.